CST: 28/07/2016 17:21:07   

FluoroPharma Medical Announces Details for Investor Call on January 6th

204 Days ago

MONTCLAIR, NJ --(Marketwired - January 05, 2016) - FluoroPharma Medical Inc., (OTCQB: FPMI) today announced that the company will conduct a conference call with the investment community, scheduled at 4:00 p.m. EST on Wednesday, January 6, 2016. The objectives of the call are to introduce Thomas H. Tulip, Ph.D., the company's new President and Chief Executive Officer, share his vision for the company, and address questions from investors.

Questions may be submitted prior to the call by posting to info@fluoropharma.com.

Participants who would like to ask questions during the question and answer session must participate by telephone. Participants are encouraged to dial-in fifteen minutes before the conference call begins.

Investors and the public are invited to access the live audio cast:

Event: FluoroPharma Medical, Inc. Management Introduction

Date and Time: Wednesday, January 6th, 4:00 PM EST

Live participant dial-in (Toll-free US and Canada): 877-407-8129
Live participant dial-in (International): 201-493-6710

The audio replay will be available until January 20, 2016:

Replay dial-in (Toll-free US and Canada): 877-660-6853
Replay dial-in (International): 201-612-7415

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The company has licensed technology from the Massachusetts General Hospital in Boston. The company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

FluoroPharma's initial focus is the development of breakthrough PET imaging agents and the company is advancing two products in clinical trials for assessment of acute and chronic forms of heart disease. These novel agents have been designed to rapidly target myocardial cells. Other active programs include the development of agents that could potentially be used for imaging specific cancers. In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia and Mexico. For more information on the company, please visit: www.fluoropharma.com.

Forward-Looking Statements

Except for historical information contained herein, this release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in FluoroPharma's business. Examples of forward-looking statements include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and FluoroPharma undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Investor Contact:

Robert B. Prag
President
The Del Mar Consulting Group, Inc.
858-794-9500
bprag@delmarconsulting.com

or

Scott Wilfong
President 
Alex Partners, LLC 
425-242-0891 
scott@alexpartnersllc.com